Seiichi Tawara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Seiichi Tawara has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Takahiro Kodama
Department of Gastroenterology and Hepatology The University of Osaka Graduate School of Medicine Suita Osaka Japan
4 shared publications - Akira Nishio
Department of Gastroenterology and Hepatology, Japan Community Healthcare Organization, Osaka Hospital, Osaka, Japan
3 shared publications Takayuki Yakushijin
Department of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka, Japan
3 shared publicationsYasutoshi Nozaki
Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Japan
3 shared publicationsHayato Hikita
Department of Gastroenterology and Hepatology, The University of Osaka, Suita, Japan
2 shared publications- Hayato Hikita
Department of Gastroenterology and Hepatology The University of Osaka Graduate School of Medicine Suita Osaka Japan
2 shared publications
Latest Publications
- Open Access
- 26 May 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (6)
Monocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy
Background: Although nucleos(t)ide analogs (NAs) suppress HBV replication, functional cure—defined by hepatitis B surface antigen (HBsAg) loss—is rarely achieved in chronic hepatitis B (CHB). Immune correlates of HBsAg decline may inform new therapeutic strategies. Methods: We profiled peripheral blood mononuclear cells (PBMCs) from NA-treated CHB patients with declining versus sustained HBsAg levels by single-cell RNA sequencing (scRNA-seq), followed by validation in an independent multicenter cohort using transcriptomic and functional assays. In a retrospective cohort, we evaluated serum interleukin-1β (IL-1β) as a predictor of HBsAg decline during long-term follow-up. Results: scRNA-seq revealed that CD14 + CD16 − classical monocytes in the HBsAg-declining group expressed significantly higher levels of IL-1β, along with genes involved in antigen presentation and phagocytosis. In the validation cohort, IL-1β expression in circulating CD14 + classical monocytes was also significantly higher in the declining group. Ex vivo stimulation assays demonstrated that recombinant HBsAg induced IL-1β production in monocytes, with stronger responses in the declining group. Recombinant IL-1β suppressed HBsAg secretion from HBV-producing HepG2.2.15 cells in vitro in a dose-dependent manner. In a longitudinal cohort, elevated serum IL-1β predicted subsequent HBsAg decline with an AUROC of 0.71. Multivariate analysis confirmed IL-1β as an independent predictor. Conclusions: Monocyte-derived IL-1β is linked to HBsAg decline during NA therapy and may serve as both a predictive biomarker and a potential therapeutic target to achieve functional cure.
- 26 May 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (6)
Open AccessMonocyte-derived IL-1β predicts and promotes HBsAg decline in chronic hepatitis B patients under nucleoside analogue therapy
Background: Although nucleos(t)ide analogs (NAs) suppress HBV replication, functional cure—defined by hepatitis B surface antigen (HBsAg) loss—is rarely achieved in chronic hepatitis B (CHB). Immune correlates of HBsAg decline may inform new therapeutic strategies. Methods: We profiled peripheral blood mononuclear cells (PBMCs) from NA-treated CHB patients with declining versus sustained HBsAg levels by single-cell RNA sequencing (scRNA-seq), followed by validation in an independent multicenter cohort using transcriptomic and functional assays. In a retrospective cohort, we evaluated serum interleukin-1β (IL-1β) as a predictor of HBsAg decline during long-term follow-up. Results: scRNA-seq revealed that CD14 + CD16 − classical monocytes in the HBsAg-declining group expressed significantly higher levels of IL-1β, along with genes involved in antigen presentation and phagocytosis. In the validation cohort, IL-1β expression in circulating CD14 + classical monocytes was also significantly higher in the declining group. Ex vivo stimulation assays demonstrated that recombinant HBsAg induced IL-1β production in monocytes, with stronger responses in the declining group. Recombinant IL-1β suppressed HBsAg secretion from HBV-producing HepG2.2.15 cells in vitro in a dose-dependent manner. In a longitudinal cohort, elevated serum IL-1β predicted subsequent HBsAg decline with an AUROC of 0.71. Multivariate analysis confirmed IL-1β as an independent predictor. Conclusions: Monocyte-derived IL-1β is linked to HBsAg decline during NA therapy and may serve as both a predictive biomarker and a potential therapeutic target to achieve functional cure.
- Open Access
- 9 April 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (4) , e013384
Carbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Background: Atezolizumab plus bevacizumab (Atez/Bev) has become the first-line therapy for unresectable hepatocellular carcinoma (HCC). However, reliable biomarkers to predict therapeutic response remain lacking. Methods: We conducted a high-throughput plasma proteomic screen using the Olink proximity extension assay to identify predictive biomarkers in 78 patients with unresectable HCC treated with Atez/Bev. Validation was performed in an independent cohort of 89 patients. Tumorous expression of the lead candidate, carbonic anhydrase 9 (CA9), was examined using transcriptomic and single-cell analyses. Functional studies were performed in a syngeneic mouse model using Car9-overexpressing hepatoma cells, treated with anti-programmed death-ligand 1/vascular endothelial growth factor antibodies, with or without a CA9 inhibitor. Results: High plasma CA9 levels were significantly associated with poor objective response rate, disease control rate, progression-free survival, and overall survival in both discovery and validation cohorts. Multivariable analysis confirmed CA9 as an independent predictor of treatment resistance and poor outcomes. Tumorous CA9 expression correlated strongly with circulating CA9 and was restricted to malignant cells. In vivo, tumors overexpressing Car9 showed resistance to Atez/Bev therapy, characterized by reduced CD8+T cell infiltration, suppressed cytotoxic gene expression, enrichment of M2-like macrophages, and pro-angiogenic signaling. The addition of a CA9 inhibitor reversed resistance and restored antitumor efficacy of Atez/Bev in this model. Conclusions: Tumor-derived circulating CA9 is a predictive biomarker and functional driver of resistance to Atez/Bev therapy in HCC. Targeting CA9 may enhance therapeutic response.
- 9 April 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (4) , e013384
Open AccessCarbonic anhydrase 9 as a circulating biomarker and therapeutic target in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Background: Atezolizumab plus bevacizumab (Atez/Bev) has become the first-line therapy for unresectable hepatocellular carcinoma (HCC). However, reliable biomarkers to predict therapeutic response remain lacking. Methods: We conducted a high-throughput plasma proteomic screen using the Olink proximity extension assay to identify predictive biomarkers in 78 patients with unresectable HCC treated with Atez/Bev. Validation was performed in an independent cohort of 89 patients. Tumorous expression of the lead candidate, carbonic anhydrase 9 (CA9), was examined using transcriptomic and single-cell analyses. Functional studies were performed in a syngeneic mouse model using Car9-overexpressing hepatoma cells, treated with anti-programmed death-ligand 1/vascular endothelial growth factor antibodies, with or without a CA9 inhibitor. Results: High plasma CA9 levels were significantly associated with poor objective response rate, disease control rate, progression-free survival, and overall survival in both discovery and validation cohorts. Multivariable analysis confirmed CA9 as an independent predictor of treatment resistance and poor outcomes. Tumorous CA9 expression correlated strongly with circulating CA9 and was restricted to malignant cells. In vivo, tumors overexpressing Car9 showed resistance to Atez/Bev therapy, characterized by reduced CD8+T cell infiltration, suppressed cytotoxic gene expression, enrichment of M2-like macrophages, and pro-angiogenic signaling. The addition of a CA9 inhibitor reversed resistance and restored antitumor efficacy of Atez/Bev in this model. Conclusions: Tumor-derived circulating CA9 is a predictive biomarker and functional driver of resistance to Atez/Bev therapy in HCC. Targeting CA9 may enhance therapeutic response.
- Open Access
- 30 March 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (3) , e013648
Systemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma
Background: Combination immunotherapies such as atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre) improve outcomes in advanced hepatocellular carcinoma (HCC), yet systemic immune mechanisms underlying response remain incompletely defined. Methods: We performed single-cell RNA sequencing with CITE-seq on peripheral blood mononuclear cells from 19 advanced HCC patients (Atez/Bev: 5 responders (R), 5 non-responders (NR); Dur/Tre: 4 R, 5 NR) before and during treatment, yielding 345 962 single-cell transcriptomes spanning 22 immune cell clusters. Analysis included transcriptional profiling, gene set enrichment analysis, T cell receptor (TCR) repertoire analysis, and CellChat-based intercellular communication modeling. Results: Baseline comparisons revealed distinct systemic immune states by etiology: non-viral HCC exhibited CD8 + T cells with heightened cytotoxic and memory-associated signatures. Under Atez/Bev, CD14 + monocytes in responders were reprogrammed toward antigen-presenting and lymphocyte-supporting functions, while PRKCH + NK cells acquired a robust cytotoxic program reinforced by monocyte–NK interactions via ICAM–integrin and HLA-E–NKG2C axes. In contrast, Dur/Tre responders exhibited CD14 + monocyte programs enriched in inflammatory and interferon-driven antigen presentation, alongside transcriptional reprogramming of CD8 + central memory T cells into an effector-ready state with strong crosstalk to monocytes. TCR analysis revealed regimen-specific differences: clonotype expansion occurred irrespective of response under Atez/Bev, whereas Dur/Tre responders showed both clonotype expansion and higher pretreatment CD8 + T cell diversity, with expanded clones displaying cytotoxic and interferon-responsive profiles. Pretreatment immune composition, including naïve CD4 + T cells and PRKCH + NK cells for Atez/Bev and conventional dendritic cells for Dur/Tre, also predicted response. Conclusions: Our findings reveal regimen-specific systemic immune mechanisms in advanced HCC: Atez/Bev amplifies monocyte–NK cytotoxic axes, whereas Dur/Tre enhances monocyte–T cell inflammatory networks and TCR repertoire diversity. These insights highlight distinct predictive biomarkers and support regimen-tailored immunotherapy in HCC.
- 30 March 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (3) , e013648
Open AccessSystemic immune profiling uncovers divergent mechanisms and predictive biomarkers of response to combination immunotherapies in hepatocellular carcinoma
Background: Combination immunotherapies such as atezolizumab plus bevacizumab (Atez/Bev) and durvalumab plus tremelimumab (Dur/Tre) improve outcomes in advanced hepatocellular carcinoma (HCC), yet systemic immune mechanisms underlying response remain incompletely defined. Methods: We performed single-cell RNA sequencing with CITE-seq on peripheral blood mononuclear cells from 19 advanced HCC patients (Atez/Bev: 5 responders (R), 5 non-responders (NR); Dur/Tre: 4 R, 5 NR) before and during treatment, yielding 345 962 single-cell transcriptomes spanning 22 immune cell clusters. Analysis included transcriptional profiling, gene set enrichment analysis, T cell receptor (TCR) repertoire analysis, and CellChat-based intercellular communication modeling. Results: Baseline comparisons revealed distinct systemic immune states by etiology: non-viral HCC exhibited CD8 + T cells with heightened cytotoxic and memory-associated signatures. Under Atez/Bev, CD14 + monocytes in responders were reprogrammed toward antigen-presenting and lymphocyte-supporting functions, while PRKCH + NK cells acquired a robust cytotoxic program reinforced by monocyte–NK interactions via ICAM–integrin and HLA-E–NKG2C axes. In contrast, Dur/Tre responders exhibited CD14 + monocyte programs enriched in inflammatory and interferon-driven antigen presentation, alongside transcriptional reprogramming of CD8 + central memory T cells into an effector-ready state with strong crosstalk to monocytes. TCR analysis revealed regimen-specific differences: clonotype expansion occurred irrespective of response under Atez/Bev, whereas Dur/Tre responders showed both clonotype expansion and higher pretreatment CD8 + T cell diversity, with expanded clones displaying cytotoxic and interferon-responsive profiles. Pretreatment immune composition, including naïve CD4 + T cells and PRKCH + NK cells for Atez/Bev and conventional dendritic cells for Dur/Tre, also predicted response. Conclusions: Our findings reveal regimen-specific systemic immune mechanisms in advanced HCC: Atez/Bev amplifies monocyte–NK cytotoxic axes, whereas Dur/Tre enhances monocyte–T cell inflammatory networks and TCR repertoire diversity. These insights highlight distinct predictive biomarkers and support regimen-tailored immunotherapy in HCC.
- Open Access
- 21 January 2026
- Published by Wiley in International Journal of Hepatology
- Vol. 2026 (1)
Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C
Aim: The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (GLE) and pibrentasvir (PIB), to investigate the clinical challenges associated with HCV treatment. Methods: A total of 141 consecutive patients who underwent GLE/PIB therapy for chronic HCV infection between December 2017 and June 2021 were enrolled. Patient backgrounds and adherence were retrospectively analyzed. Results: Median patient age was 61 years. Eighteen patients had a history of injecting drug use (IDU), accounting for 13% of the sample. At the end of treatment, three patients (2.1%) self‐discontinued hospital visits. The number of patients who self‐discontinued hospital visits gradually increased over time to 9 (6.4%) at 4 weeks after treatment, 16 (11.3%) at 12 weeks after treatment, and 24 (17.0%) at 24 weeks after treatment. The sustained viral response rate after 12 weeks, excluding patients who self‐discontinued hospital visits, was 96.8% (121/125). In a multivariate analysis, age < 60 years and a history of IDU were significant factors associated with the self‐discontinuation of hospital visits. The hazard ratio (HR) for those younger than 60 years old was 3.17 ( p = 0.012), whereas the HR for those with a history of IDU was 2.41 ( p = 0.036). Conclusions: History of IDU and younger age were significantly associated with poor adherence to GLE/PIB treatment.
- 21 January 2026
- Published by Wiley in International Journal of Hepatology
- Vol. 2026 (1)
Open AccessInjecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C
Aim: The use of direct‐acting antivirals (DAAs) against the Hepatitis C virus (HCV) has rapidly expanded since their introduction. However, some patients with HCV infection may still not receive appropriate medical care. This study analyzed the characteristics and adherence of the population receiving therapy with two later‐generation DAAs, glecaprevir (GLE) and pibrentasvir (PIB), to investigate the clinical challenges associated with HCV treatment. Methods: A total of 141 consecutive patients who underwent GLE/PIB therapy for chronic HCV infection between December 2017 and June 2021 were enrolled. Patient backgrounds and adherence were retrospectively analyzed. Results: Median patient age was 61 years. Eighteen patients had a history of injecting drug use (IDU), accounting for 13% of the sample. At the end of treatment, three patients (2.1%) self‐discontinued hospital visits. The number of patients who self‐discontinued hospital visits gradually increased over time to 9 (6.4%) at 4 weeks after treatment, 16 (11.3%) at 12 weeks after treatment, and 24 (17.0%) at 24 weeks after treatment. The sustained viral response rate after 12 weeks, excluding patients who self‐discontinued hospital visits, was 96.8% (121/125). In a multivariate analysis, age < 60 years and a history of IDU were significant factors associated with the self‐discontinuation of hospital visits. The hazard ratio (HR) for those younger than 60 years old was 3.17 ( p = 0.012), whereas the HR for those with a history of IDU was 2.41 ( p = 0.036). Conclusions: History of IDU and younger age were significantly associated with poor adherence to GLE/PIB treatment.
- Open Access
- 1 January 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (2) , e6957
Comparison of percutaneous ablation and hepatectomy for liver metastasis: A single center retrospective study
Aim: To investigate the current treatment for liver metastasis and clarify the indications for percutaneous thermal ablation for liver metastasis.Methods: Ninety‐two patients were enrolled and retrospectively analyzed. The patients underwent hepatectomy and/or percutaneous thermal ablation for liver metastases between January 2012 and December 2018. Twenty‐six patients who underwent ablation treatment and seven patients who underwent both ablation and hepatectomy were included in the ablation treatment group (group A). We compared these patients with 59 patients who underwent hepatectomy only (group H). Subgroup analyses were performed between ablation (group AC) for colorectal liver metastasis and hepatectomy (group HC) for colorectal liver metastasis in 17 and 53 patients, respectively.Results: The percentage of liver metastases other than colorectal cancer in group A was higher than that in the group H. Maximum tumor size in group A was significantly smaller than that in group H. Similarly, the patients in group AC were significantly older and demonstrated higher total bilirubin, lower serum albumin, and lower platelet counts than those in group HC. Overall survival was poorer in the AC group than that in the HC group. However, no differences were observed at metastasis ≤2 cm in size.Conclusions: Percutaneous thermal ablation was performed for many cancer types than hepatectomy. It is performed in elderly patients. We suggested that ablation for colorectal liver metastasis sized ≤2 cm is a suitable indication.
- 1 January 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (2) , e6957
Open AccessComparison of percutaneous ablation and hepatectomy for liver metastasis: A single center retrospective study
Aim: To investigate the current treatment for liver metastasis and clarify the indications for percutaneous thermal ablation for liver metastasis.Methods: Ninety‐two patients were enrolled and retrospectively analyzed. The patients underwent hepatectomy and/or percutaneous thermal ablation for liver metastases between January 2012 and December 2018. Twenty‐six patients who underwent ablation treatment and seven patients who underwent both ablation and hepatectomy were included in the ablation treatment group (group A). We compared these patients with 59 patients who underwent hepatectomy only (group H). Subgroup analyses were performed between ablation (group AC) for colorectal liver metastasis and hepatectomy (group HC) for colorectal liver metastasis in 17 and 53 patients, respectively.Results: The percentage of liver metastases other than colorectal cancer in group A was higher than that in the group H. Maximum tumor size in group A was significantly smaller than that in group H. Similarly, the patients in group AC were significantly older and demonstrated higher total bilirubin, lower serum albumin, and lower platelet counts than those in group HC. Overall survival was poorer in the AC group than that in the HC group. However, no differences were observed at metastasis ≤2 cm in size.Conclusions: Percutaneous thermal ablation was performed for many cancer types than hepatectomy. It is performed in elderly patients. We suggested that ablation for colorectal liver metastasis sized ≤2 cm is a suitable indication.
- Open Access
- 26 April 2022
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 37 (6) , 1148-1155
Prognostic impact of worsening of esophageal varices after balloon‐occluded retrograde transvenous obliteration
Balloon-occluded retrograde transvenous obliteration (BRTO) is widely performed for treating gastric varices (GVs). However, worsening of esophageal varices (EVs) can be observed after BRTO. This study aimed to investigate the impact of EV worsening on prognosis after BRTO. Overall, 258 patients who underwent initial BRTO for GV treatment between January 2004 and May 2019 at 12 institutions were retrospectively registered. Technical success was achieved in 235 patients (91.1%). Based on the exclusion criteria, 37 patients were excluded, and 198 were evaluated. The cumulative worsening rates of EVs at 1, 2, and 3 years were 39.0%, 59.4%, and 68.4%, respectively. In the univariate Cox proportional hazards model, sex, EV size, history of EV treatment, left gastric vein dilatation, platelet count, aspartate transaminase (AST), alanine aminotransferase (ALT), total bilirubin, albumin, albumin-bilirubin score, prothrombin time-international normalized ratio, fibrosis-4 index, AST to platelet ratio index, and spleen width were significantly associated with worsening of EV after BRTO. Multivariate analysis showed that sex (adjusted hazard ratio [aHR] 1.72; 95% confidence interval [CI] 1.03-2.86; P = 0.04), left gastric vein dilatation (aHR 1.90; 95% CI 1.17-3.10; P = 0.01), ALT (aHR 1.01; 95% CI 1.00-1.03; P = 0.02), albumin (aHR 0.61; 95% CI 0.43-0.87; P < 0.01), and spleen width (aHR 1.02; 95% CI 1.01-1.03; P < 0.01) were independent risk factors for worsening of EV after BRTO. Patients with EV worsening within 1 year after BRTO had a significantly worse prognosis than the other patients (P = 0.007). Early worsening of EV after BRTO was associated with poor prognosis after BRTO.
- 26 April 2022
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 37 (6) , 1148-1155
Open AccessPrognostic impact of worsening of esophageal varices after balloon‐occluded retrograde transvenous obliteration
Balloon-occluded retrograde transvenous obliteration (BRTO) is widely performed for treating gastric varices (GVs). However, worsening of esophageal varices (EVs) can be observed after BRTO. This study aimed to investigate the impact of EV worsening on prognosis after BRTO. Overall, 258 patients who underwent initial BRTO for GV treatment between January 2004 and May 2019 at 12 institutions were retrospectively registered. Technical success was achieved in 235 patients (91.1%). Based on the exclusion criteria, 37 patients were excluded, and 198 were evaluated. The cumulative worsening rates of EVs at 1, 2, and 3 years were 39.0%, 59.4%, and 68.4%, respectively. In the univariate Cox proportional hazards model, sex, EV size, history of EV treatment, left gastric vein dilatation, platelet count, aspartate transaminase (AST), alanine aminotransferase (ALT), total bilirubin, albumin, albumin-bilirubin score, prothrombin time-international normalized ratio, fibrosis-4 index, AST to platelet ratio index, and spleen width were significantly associated with worsening of EV after BRTO. Multivariate analysis showed that sex (adjusted hazard ratio [aHR] 1.72; 95% confidence interval [CI] 1.03-2.86; P = 0.04), left gastric vein dilatation (aHR 1.90; 95% CI 1.17-3.10; P = 0.01), ALT (aHR 1.01; 95% CI 1.00-1.03; P = 0.02), albumin (aHR 0.61; 95% CI 0.43-0.87; P < 0.01), and spleen width (aHR 1.02; 95% CI 1.01-1.03; P < 0.01) were independent risk factors for worsening of EV after BRTO. Patients with EV worsening within 1 year after BRTO had a significantly worse prognosis than the other patients (P = 0.007). Early worsening of EV after BRTO was associated with poor prognosis after BRTO.